Eltrombopag/eltrombopag new medical insurance reimbursement policy

Eltrombopag/Eltrombopag (Eltrombopag) has been included in the scope of Class B medical insurance reimbursement in the new medical insurance reimbursement policy announced by the National Medical Insurance Administration. This policy has begun to be officially implemented, and patients who meet the indications can be reimbursed through the national medical insurance.

The implementation of this new policy means that eligible patients can receive a certain degree of financial support and reduce their financial burden when treated with eltrombopag. However, it should be noted that the medical insurance reimbursement policy still sets some restrictions. Only patients who meet specific conditions can enjoy medical insurance reimbursement benefits, such as adults and children aged 6 years and above with chronic immune (idiopathic) thrombocytopenia (ITP) who have previously had poor response to glucocorticoids, immunoglobulins and other treatments, and patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive treatment in the past. This means that not all patients taking eltrombopag will be reimbursed by health insurance.

Patients need to purchase Eltrombopag at designated medical institutions and complete the reimbursement procedures. This requires patients to choose hospitals or pharmacies that comply with medical insurance policies to ensure smooth reimbursement. In addition, the medical insurance reimbursement policy also stipulates the dosage and course of treatment of Eltrombopag, and any portion beyond the prescribed range will not be reimbursed. Currently, the original drug of Eltrombopag is available in the domestic market under the name of Eltrombopag ethanolamine tablets, with the price of each box ranging from RMB 2,000 to RMB 4,000. When using eltrombopag, patients need to strictly follow the doctor's recommendations and the provisions of the medical insurance policy to ensure that they can obtain the maximum reimbursement benefit.